Genetic testing for cancer risk
Regeneron to Acquire 23andMe Out of Bankruptcy for $256 Million
Regeneron; 23andMe; acquisition; bankruptcy; genetic testing; genome; personal genome service; total health; research services; data privacy
23andMe Restructures, Cuts 40% of Workforce and Ends Therapeutics Division Amid Financial Struggles
23andMe, layoffs, therapeutics division, financial struggles, genetic testing, data security